Voclosporin Ophthalmic Solution (VOS), a topical formulation of voclosporin, is an aqueous, preservative free nanomicellar solution we are developing for the treatment of dry eye syndrome (DES). There are currently three FDA approved prescription therapies for the treatment of DES, two of which are CNIs. We believe there are opportunities to improve upon current therapies by potentially decreasing the time to achieve objective and subjective relief of DES signs and symptoms.
The AUDREY clinical trial is a US-based, randomized, double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and safety of VOS in subjects with DES and will enroll approximately 480 subjects. Top-line results from the AUDREY clinical trial are anticipated during the fourth quarter of 2020.